Interchangeable Biosimilar Designations Shouldn't Be Forever, Innovators Say

US FDA may need to withdraw previous interchangeability determination due to new indications or manufacturing changes, reference product companies say; generic firms say prior interchangeability designation should apply to new indications absent significant scientific questions.